董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gerald Farrell | 男 | Director | 58 | 5.40万美元 | 未持股 | 2019-04-12 |
| Gerd U. Auffarth | 男 | Director | 53 | 10.65万美元 | 未持股 | 2019-04-12 |
| Mark Yung | 男 | Chief Executive Officer and Executive Chairman of the Board | 44 | 未披露 | 未持股 | 2019-04-12 |
| Robert J. Cresci | 男 | Director | 74 | 10.15万美元 | 未持股 | 2019-04-12 |
| Zohar Loshitzer | 男 | Director | 66 | 4.65万美元 | 未持股 | 2019-04-12 |
| Richard Ressler | 男 | Director | 65 | 3.90万美元 | 未持股 | 2019-04-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Yung | 男 | Chief Executive Officer and Executive Chairman of the Board | 44 | 未披露 | 未持股 | 2019-04-12 |
| Casey Lind | 女 | Chief Operating Officer | 55 | 未披露 | 未持股 | 2019-04-12 |
| Valeriano Lima | 男 | Corporate Controller and Company Secretary | 38 | 未披露 | 未持股 | 2019-04-12 |
董事简历
中英对照 | 中文 | 英文- Gerald Farrell
-
Gerald Farrell自2016年1月起担任Presbia PLC董事。Farrell参与制药行业已超过25年时间，他的大部分成功的职业生涯都在英国和爱尔兰Eli Lilly Company Limited任职。Farrell在Eli Lilly的任职包括担任总经理，领导爱尔兰的商业销售和营销；英国战略、商业和业务主管，负责战旗战略规划和业务运营；其他合规、产品、销售和规划相关职位。Farrell持有University College, Cork植物生物技术博士学位；戈尔韦University College植物科学荣誉理学学士学位；高等学历教育。Farrell现任UCD Michael Smurfit Graduate Business School董事；Irish Pharmaceutical Healthcare Association现任董事和前任总裁；现任Dublin Chamber of Commerce委员会成员。Farrell从2003年到2014年担任Eli Lilly 和 Company Ireland Ltd.董事。
Gerald Farrell has served as a director of Presbia PLC since January 2016. Dr. Farrell has been involved in the pharmaceutical industry for more than 25 years, and worked for Eli Lilly Company Limited in Ireland and the United Kingdom for the majority of his successful career. Dr. Farrell’s tenure at Eli Lilly included positions of Managing Director, leading the commercial sales and marketing in Ireland, Director Strategy, Commercial and Business in the UK accountable for long-term strategic planning and business operations as well as other positions related to compliance, production, sales, and planning. Dr. Farrell earned a Ph.D. Plant Biotechnology from University College, Cork, and a BSc Honors - Plant Science and Higher Diploma Education with Honors from University College, Galway. Dr. Farrell serves on the Board for UCD Michael Smurfit Graduate Business School, serves as a director, and previously served as president, for Irish Pharmaceutical Healthcare Association, and serves as a council member for the Dublin Chamber of Commerce. Previously, from 2003 until 2014 Dr. Farrell served as a director of Eli Lilly and Company Ireland Ltd. - Gerald Farrell自2016年1月起担任Presbia PLC董事。Farrell参与制药行业已超过25年时间，他的大部分成功的职业生涯都在英国和爱尔兰Eli Lilly Company Limited任职。Farrell在Eli Lilly的任职包括担任总经理，领导爱尔兰的商业销售和营销；英国战略、商业和业务主管，负责战旗战略规划和业务运营；其他合规、产品、销售和规划相关职位。Farrell持有University College, Cork植物生物技术博士学位；戈尔韦University College植物科学荣誉理学学士学位；高等学历教育。Farrell现任UCD Michael Smurfit Graduate Business School董事；Irish Pharmaceutical Healthcare Association现任董事和前任总裁；现任Dublin Chamber of Commerce委员会成员。Farrell从2003年到2014年担任Eli Lilly 和 Company Ireland Ltd.董事。
- Gerald Farrell has served as a director of Presbia PLC since January 2016. Dr. Farrell has been involved in the pharmaceutical industry for more than 25 years, and worked for Eli Lilly Company Limited in Ireland and the United Kingdom for the majority of his successful career. Dr. Farrell’s tenure at Eli Lilly included positions of Managing Director, leading the commercial sales and marketing in Ireland, Director Strategy, Commercial and Business in the UK accountable for long-term strategic planning and business operations as well as other positions related to compliance, production, sales, and planning. Dr. Farrell earned a Ph.D. Plant Biotechnology from University College, Cork, and a BSc Honors - Plant Science and Higher Diploma Education with Honors from University College, Galway. Dr. Farrell serves on the Board for UCD Michael Smurfit Graduate Business School, serves as a director, and previously served as president, for Irish Pharmaceutical Healthcare Association, and serves as a council member for the Dublin Chamber of Commerce. Previously, from 2003 until 2014 Dr. Farrell served as a director of Eli Lilly and Company Ireland Ltd.
- Gerd U. Auffarth
-
Gerd U. Auffarth自2015年8月起担任Presbia PLC董事；Auffarth还自2011年4月起担任德国Ruprecht-Karls-University of Heidelberg眼科学主管和系主任。Auffarth自2006年8月起担任International Vision Correction Research Centre（一家研究中心，专注于白内障和屈光手术、实验室研究和眼部药理学）主管。他自2012年6月起担任The David J Apple International Laboratory for Ophthalmic Pathology（提供眼科器械分析）主管。他自2006年8月起担任Steinbeis Technology Transfer Research Company IVCRC（对公司进行试验，包括与University Eye Clinic of Heidelberg合作的眼科医疗设备业务领域的初创公司）创始人和首席执行官。他自2012年3月起担任总裁German Society for Intraocular Lens Implantation and Refractive Surgery；自1999年3月起担任董事。他自2012年9月起担任German Ophthalmological Society DOG董事；自2005年9月起担任European Society for Cataract and Refractive Surgeons （ESCRS）荣誉董事。他持有德国RWTH Aachen Medical School, Aachen University of Technology医学硕士学位；德国Ruprecht-Karls-University of Heidelberg眼科和眼部病变教授。
Gerd U. Auffarth has served as a director of Presbia PLC since August 2015 and Dr. Auffarth has also served as the Director and Chairman of the Department of Ophthalmology at the Ruprecht-Karls-University of Heidelberg, Germany since April 2011. Since August 2006 Dr. Auffarth has been the Director of the International Vision Correction Research Centre, a research center focusing on cataract and refractive surgery, laboratory studies, and ocular pharmacology. Since June 2012 he has been the Director of The David J Apple International Laboratory for Ophthalmic Pathology, which provides analyses on ophthalmic devices. Since August 2006 he has served as the Founder and Chief Executive Officer of' Steinbeis Technology Transfer Research Company IVCRC, which carries out research with companies, including start-up companies, in the ophthalmic medical device business in cooperation with the University Eye Clinic of Heidelberg. Since March 2012 he has served as the President of the German Society for Intraocular Lens Implantation and Refractive Surgery, and he has served on the board of this society since March 1999. Since September 2012 he has served as a member of the board of the German Ophthalmological Society DOG, and since September 2005 he has served as an emeritus member of the board of the European Society for Cataract and Refractive Surgeons (ESCRS). He received an M.D. degree from the RWTH Aachen Medical School, Aachen University of Technology, Germany, and a Professorship in Ophthalmology and Ocular Pathology of the Ruprecht-Karls-University of Heidelberg, Germany. - Gerd U. Auffarth自2015年8月起担任Presbia PLC董事；Auffarth还自2011年4月起担任德国Ruprecht-Karls-University of Heidelberg眼科学主管和系主任。Auffarth自2006年8月起担任International Vision Correction Research Centre（一家研究中心，专注于白内障和屈光手术、实验室研究和眼部药理学）主管。他自2012年6月起担任The David J Apple International Laboratory for Ophthalmic Pathology（提供眼科器械分析）主管。他自2006年8月起担任Steinbeis Technology Transfer Research Company IVCRC（对公司进行试验，包括与University Eye Clinic of Heidelberg合作的眼科医疗设备业务领域的初创公司）创始人和首席执行官。他自2012年3月起担任总裁German Society for Intraocular Lens Implantation and Refractive Surgery；自1999年3月起担任董事。他自2012年9月起担任German Ophthalmological Society DOG董事；自2005年9月起担任European Society for Cataract and Refractive Surgeons （ESCRS）荣誉董事。他持有德国RWTH Aachen Medical School, Aachen University of Technology医学硕士学位；德国Ruprecht-Karls-University of Heidelberg眼科和眼部病变教授。
- Gerd U. Auffarth has served as a director of Presbia PLC since August 2015 and Dr. Auffarth has also served as the Director and Chairman of the Department of Ophthalmology at the Ruprecht-Karls-University of Heidelberg, Germany since April 2011. Since August 2006 Dr. Auffarth has been the Director of the International Vision Correction Research Centre, a research center focusing on cataract and refractive surgery, laboratory studies, and ocular pharmacology. Since June 2012 he has been the Director of The David J Apple International Laboratory for Ophthalmic Pathology, which provides analyses on ophthalmic devices. Since August 2006 he has served as the Founder and Chief Executive Officer of' Steinbeis Technology Transfer Research Company IVCRC, which carries out research with companies, including start-up companies, in the ophthalmic medical device business in cooperation with the University Eye Clinic of Heidelberg. Since March 2012 he has served as the President of the German Society for Intraocular Lens Implantation and Refractive Surgery, and he has served on the board of this society since March 1999. Since September 2012 he has served as a member of the board of the German Ophthalmological Society DOG, and since September 2005 he has served as an emeritus member of the board of the European Society for Cataract and Refractive Surgeons (ESCRS). He received an M.D. degree from the RWTH Aachen Medical School, Aachen University of Technology, Germany, and a Professorship in Ophthalmology and Ocular Pathology of the Ruprecht-Karls-University of Heidelberg, Germany.
- Mark Yung
-
Mark Yung于2017年12月11日当选为Presbia Plc董事会执行主席兼首席执行官。容先生是OCV Management，LLC“；OCV”；的联合创始人兼管理负责人，OCV”；是一家位于洛杉矶的技术和生命科学公司的投资者，所有者和运营商，该公司成立于2016年，由Richard Ressler（我们的董事之一，也是我们公司大多数普通股的实益拥有人）持有多数股权。此前，他曾担任Orchard Capital公司（他于2006年加入的公司）的董事总经理。通过与OCV和Orchard Capital的合作，容先生一直并将继续担任各种高级职务，其中包括眼科设备公司Presbia Plc（纳斯达克市场代码:LENS）的董事长兼首席执行官，以及Environmental Solutions Worldwide，Inc.的董事会执行主席，一家专注于减少柴油排放的清洁技术公司，担任Polymer Plainfield Holdings，Inc.的首席财务官和董事，该公司是一家OEM汽车供应商，业务遍及美国、加拿大、墨西哥和加勒比地区，担任Vantage Surgical Systems，Inc.的董事会主席，以及担任Coreolis Holdings和Tradewinds Holdings的董事和/或官员。加入Orchard Capital Corp.之前，Yung先生是纽约花旗集团（Citigroup）和荷兰阿姆斯特丹荷兰银行（ABN AMRO）企业战略与并购集团的高级副总裁。担任公司战略职务之前，Yung先生是JPMorgan Partners（“；JPMP”；）的投资专业人士。在JPMP，Yung先生专注于拉丁美洲的风险投资，增长股权和买断交易，并担任该地区各种新兴公司的董事会成员。Yung先生于1996年在Chase Securities，Inc.开始他的职业生涯，专注于跨境收购和私有化的杠杆融资。容先生是Pacwest Bancorp公司（Nasdaq“；PACW”；）的独立董事。Yung先生拥有康奈尔大学（Cornell University）学士学位和欧洲工商管理学院（INSEAD）工商管理硕士学位。
Mark Yung was elected as Executive Chairman of the board and Chief Executive Officer of Presbia PLC on December 11 2017. Mr. Yung is co-founder and Managing Principal of OCV Management, LLC “OCV”, an investor, owner and operator of technology and life science companies based in Los Angeles, which was founded in 2016 and is majority-owned by Richard Ressler (one of our directors and the beneficial owner of the majority of the ordinary shares of our company). Previously, Mr. Yung was a Managing Director at Orchard Capital Corp., a firm he joined in 2006. Through his affiliation with OCV and Orchard Capital, Mr. Yung has and continues to serve in various senior capacities including, among others, as Chairman and CEO of Presbia PLC (NASDAQ: LENS), an ophthalmic device company, as Executive Chairman of the board of directors of Environmental Solutions Worldwide, Inc., a clean technology company focused on the reduction of diesel emissions, as Chief Financial Officer and director of Polymer Plainfield Holdings, Inc., an OEM automotive supplier with operations in the United States, Canada, Mexico and the Caribbean, as Chairman of the Board of Vantage Surgical Systems, Inc., and as director and/or officer of Coreolis Holdings and Tradewinds Holdings. Prior to joining Orchard Capital Corp., Mr. Yung was a Senior Vice President in the Corporate Strategy and Merger and Acquisitions groups of Citigroup in New York and ABN AMRO in Amsterdam, Netherlands. Prior to his corporate strategy roles, Mr. Yung was an investment professional at JPMorgan Partners (“JPMP”). At JPMP, Mr. Yung focused on venture capital, growth equity and buyout transactions in Latin America and served as board member for various emerging companies in the region. Mr. Yung began his career in 1996 at Chase Securities, Inc., focusing on leveraged finance for cross-border buyouts and privatizations. Mr. Yung is an Independent Director of PacWest Bancorp, Inc. (NASDAQ “PACW”). Mr. Yung holds a B.A. from Cornell University and an MBA from INSEAD. - Mark Yung于2017年12月11日当选为Presbia Plc董事会执行主席兼首席执行官。容先生是OCV Management，LLC“；OCV”；的联合创始人兼管理负责人，OCV”；是一家位于洛杉矶的技术和生命科学公司的投资者，所有者和运营商，该公司成立于2016年，由Richard Ressler（我们的董事之一，也是我们公司大多数普通股的实益拥有人）持有多数股权。此前，他曾担任Orchard Capital公司（他于2006年加入的公司）的董事总经理。通过与OCV和Orchard Capital的合作，容先生一直并将继续担任各种高级职务，其中包括眼科设备公司Presbia Plc（纳斯达克市场代码:LENS）的董事长兼首席执行官，以及Environmental Solutions Worldwide，Inc.的董事会执行主席，一家专注于减少柴油排放的清洁技术公司，担任Polymer Plainfield Holdings，Inc.的首席财务官和董事，该公司是一家OEM汽车供应商，业务遍及美国、加拿大、墨西哥和加勒比地区，担任Vantage Surgical Systems，Inc.的董事会主席，以及担任Coreolis Holdings和Tradewinds Holdings的董事和/或官员。加入Orchard Capital Corp.之前，Yung先生是纽约花旗集团（Citigroup）和荷兰阿姆斯特丹荷兰银行（ABN AMRO）企业战略与并购集团的高级副总裁。担任公司战略职务之前，Yung先生是JPMorgan Partners（“；JPMP”；）的投资专业人士。在JPMP，Yung先生专注于拉丁美洲的风险投资，增长股权和买断交易，并担任该地区各种新兴公司的董事会成员。Yung先生于1996年在Chase Securities，Inc.开始他的职业生涯，专注于跨境收购和私有化的杠杆融资。容先生是Pacwest Bancorp公司（Nasdaq“；PACW”；）的独立董事。Yung先生拥有康奈尔大学（Cornell University）学士学位和欧洲工商管理学院（INSEAD）工商管理硕士学位。
- Mark Yung was elected as Executive Chairman of the board and Chief Executive Officer of Presbia PLC on December 11 2017. Mr. Yung is co-founder and Managing Principal of OCV Management, LLC “OCV”, an investor, owner and operator of technology and life science companies based in Los Angeles, which was founded in 2016 and is majority-owned by Richard Ressler (one of our directors and the beneficial owner of the majority of the ordinary shares of our company). Previously, Mr. Yung was a Managing Director at Orchard Capital Corp., a firm he joined in 2006. Through his affiliation with OCV and Orchard Capital, Mr. Yung has and continues to serve in various senior capacities including, among others, as Chairman and CEO of Presbia PLC (NASDAQ: LENS), an ophthalmic device company, as Executive Chairman of the board of directors of Environmental Solutions Worldwide, Inc., a clean technology company focused on the reduction of diesel emissions, as Chief Financial Officer and director of Polymer Plainfield Holdings, Inc., an OEM automotive supplier with operations in the United States, Canada, Mexico and the Caribbean, as Chairman of the Board of Vantage Surgical Systems, Inc., and as director and/or officer of Coreolis Holdings and Tradewinds Holdings. Prior to joining Orchard Capital Corp., Mr. Yung was a Senior Vice President in the Corporate Strategy and Merger and Acquisitions groups of Citigroup in New York and ABN AMRO in Amsterdam, Netherlands. Prior to his corporate strategy roles, Mr. Yung was an investment professional at JPMorgan Partners (“JPMP”). At JPMP, Mr. Yung focused on venture capital, growth equity and buyout transactions in Latin America and served as board member for various emerging companies in the region. Mr. Yung began his career in 1996 at Chase Securities, Inc., focusing on leveraged finance for cross-border buyouts and privatizations. Mr. Yung is an Independent Director of PacWest Bancorp, Inc. (NASDAQ “PACW”). Mr. Yung holds a B.A. from Cornell University and an MBA from INSEAD.
- Robert J. Cresci
-
Robert J. Cresci，自1996年12月以来，他成为董事会的一员。自1990年9月以来，他Pecks Management Partners Ltd.（该公司是一个投资管理公司。）的董事总经理。他目前是j2 Global Communications, Inc.（一个提供外包、增值信息、通信服务的供应商。）和OFS Capital Corporation（一个商业发展公司）的董事会成员。他在过去的五年中，他曾在塞普拉柯公司（Sepracor Inc.是一个以研究为基础的制药公司）和SeraCare Life Sciences, Inc.（该公司是一个广泛的生物制品和服务供应商。）的董事会任职。他获得美国西点军校（the United States Military Academy）的工程学士学位和哥伦比亚大学商学院（Columbia University Graduate School of Business）的工商管理硕士学位。
Robert J. Cresci has been a managing director of Pecks Management Partners Ltd., an investment management firm, since 1990. He currently serves on the boards of j2 Global, Inc., CIM Commercial Trust Corporation, OFS Credit Company, Inc. “OFS Credit” and Hancock Park Corporate Income, Inc. (“Hancock Park”), another BDC managed by OFS Advisor. Mr. Cresci holds an undergraduate degree in Engineering from the United States Military Academy at West Point and an M.B.A. in Finance from the Columbia University Graduate School of Business. - Robert J. Cresci，自1996年12月以来，他成为董事会的一员。自1990年9月以来，他Pecks Management Partners Ltd.（该公司是一个投资管理公司。）的董事总经理。他目前是j2 Global Communications, Inc.（一个提供外包、增值信息、通信服务的供应商。）和OFS Capital Corporation（一个商业发展公司）的董事会成员。他在过去的五年中，他曾在塞普拉柯公司（Sepracor Inc.是一个以研究为基础的制药公司）和SeraCare Life Sciences, Inc.（该公司是一个广泛的生物制品和服务供应商。）的董事会任职。他获得美国西点军校（the United States Military Academy）的工程学士学位和哥伦比亚大学商学院（Columbia University Graduate School of Business）的工商管理硕士学位。
- Robert J. Cresci has been a managing director of Pecks Management Partners Ltd., an investment management firm, since 1990. He currently serves on the boards of j2 Global, Inc., CIM Commercial Trust Corporation, OFS Credit Company, Inc. “OFS Credit” and Hancock Park Corporate Income, Inc. (“Hancock Park”), another BDC managed by OFS Advisor. Mr. Cresci holds an undergraduate degree in Engineering from the United States Military Academy at West Point and an M.B.A. in Finance from the Columbia University Graduate School of Business.
- Zohar Loshitzer
-
Zohar Loshitzer，自2007年5月以来，一直是Presbia Holdings的总裁、首席执行官以及董事，自2014年2月以来，一直任Presbia PLC的总裁兼董事。自2005年以来，他曾在Orchard Capital任主要负责人，在那里他通过设计运用效率和削减成本来支持Orchard Capital的投资组合公司；以及自2000年8月以来在一家电信服务和新兴市场方案的供应商- Universal Telecom Services股份有限公司的总裁兼首席执行官。自2001年6月以来，他一直在j2 Global担任公司战略副执行总裁；1997年7月-2001年6月期间在j2 Global任首席信息官。他曾于2011年1月-2013年8月期间，是一家商业咨询公司- MTP Consulting股份有限公司的创始人、总裁。2007年1月-2010年12月期间，是另外一家商业咨询公司- Imali股份有限公司的创始人兼总裁。自1995年以来，他一直是一家电信产品的供应商- Orchard Telecom的总经理。此前，他曾在一家信息技术公司- MAI Systems公司任顾问；在一家其创立的、为老年任提供安全服务的供应商- Life Alert Emergency Response股份有限公司的总经理兼执行董事。自2011年12月以来，在公开上市的Advanced Cell Technology 股份有限公司担任董事。他是在Tel Aviv大学毕业并获得电气工程学位的。
Zohar Loshitzer has served as a director of Presbia PLC since February 2014. He served as a director of Presbia Holdings from May 2007 until its liquidation in 2015. He served as the Chief Executive Officer of Presbia PLC from February 2014 to October 2014 served as the President of Presbia PLC from February 2014 to January 2015 served as Chief Business Development Officer from January 2015 to September 2015. Since 2016 Mr. Loshitzer has served as principal at OCV. Since January 2005 Mr. Loshitzer has served as a principal at Orchard Capital. OCV and Orchard Capital are majority owned by Richard Ressler one of our directors and the beneficial owner of the majority of the ordinary shares of our company, where he supports the portfolio companies of Orchard Capital by designing operational efficiencies and cost reductions, and he has served since August 2000 as the President and Chief Executive Officer of Universal Telecom Services, Inc., a provider of telecommunications services and solutions to emerging markets. He has served as Executive Vice President of Corporate Strategy of j2 Global since June 2001 and from July 1997 through June 2001 he served as the Chief Information Officer at j2 Global. Mr. Loshitzer was the founder and President of MTP Consulting, Inc., a business consulting firm, from January 2011 to August 2013 and he was the founder and President of Imali, Inc., another business consulting firm, from January 2007 to December 2010. Since 1995 he has been a Managing Director at Orchard Telecom, a provider of telecommunications products. He previously served as a consultant to MAI Systems Corporation, a provider of information technology solutions, and as a General Manager and Managing Director at Life Alert Emergency Response, Inc., a provider of security services for the elderly, which Mr. Loshitzer co-founded. He was a director of the publicly-traded OCATA Therapeutics (formerly Advanced Cell Technology Inc.) from December 2011 to February 2016 when the company was sold to a Japanese private company. He was also a director of publicly-traded Environmental Solutions Worldwide, Inc. from January 2011 to December 2015. He graduated from Tel Aviv University with a degree in Electronics Engineering. - Zohar Loshitzer，自2007年5月以来，一直是Presbia Holdings的总裁、首席执行官以及董事，自2014年2月以来，一直任Presbia PLC的总裁兼董事。自2005年以来，他曾在Orchard Capital任主要负责人，在那里他通过设计运用效率和削减成本来支持Orchard Capital的投资组合公司；以及自2000年8月以来在一家电信服务和新兴市场方案的供应商- Universal Telecom Services股份有限公司的总裁兼首席执行官。自2001年6月以来，他一直在j2 Global担任公司战略副执行总裁；1997年7月-2001年6月期间在j2 Global任首席信息官。他曾于2011年1月-2013年8月期间，是一家商业咨询公司- MTP Consulting股份有限公司的创始人、总裁。2007年1月-2010年12月期间，是另外一家商业咨询公司- Imali股份有限公司的创始人兼总裁。自1995年以来，他一直是一家电信产品的供应商- Orchard Telecom的总经理。此前，他曾在一家信息技术公司- MAI Systems公司任顾问；在一家其创立的、为老年任提供安全服务的供应商- Life Alert Emergency Response股份有限公司的总经理兼执行董事。自2011年12月以来，在公开上市的Advanced Cell Technology 股份有限公司担任董事。他是在Tel Aviv大学毕业并获得电气工程学位的。
- Zohar Loshitzer has served as a director of Presbia PLC since February 2014. He served as a director of Presbia Holdings from May 2007 until its liquidation in 2015. He served as the Chief Executive Officer of Presbia PLC from February 2014 to October 2014 served as the President of Presbia PLC from February 2014 to January 2015 served as Chief Business Development Officer from January 2015 to September 2015. Since 2016 Mr. Loshitzer has served as principal at OCV. Since January 2005 Mr. Loshitzer has served as a principal at Orchard Capital. OCV and Orchard Capital are majority owned by Richard Ressler one of our directors and the beneficial owner of the majority of the ordinary shares of our company, where he supports the portfolio companies of Orchard Capital by designing operational efficiencies and cost reductions, and he has served since August 2000 as the President and Chief Executive Officer of Universal Telecom Services, Inc., a provider of telecommunications services and solutions to emerging markets. He has served as Executive Vice President of Corporate Strategy of j2 Global since June 2001 and from July 1997 through June 2001 he served as the Chief Information Officer at j2 Global. Mr. Loshitzer was the founder and President of MTP Consulting, Inc., a business consulting firm, from January 2011 to August 2013 and he was the founder and President of Imali, Inc., another business consulting firm, from January 2007 to December 2010. Since 1995 he has been a Managing Director at Orchard Telecom, a provider of telecommunications products. He previously served as a consultant to MAI Systems Corporation, a provider of information technology solutions, and as a General Manager and Managing Director at Life Alert Emergency Response, Inc., a provider of security services for the elderly, which Mr. Loshitzer co-founded. He was a director of the publicly-traded OCATA Therapeutics (formerly Advanced Cell Technology Inc.) from December 2011 to February 2016 when the company was sold to a Japanese private company. He was also a director of publicly-traded Environmental Solutions Worldwide, Inc. from January 2011 to December 2015. He graduated from Tel Aviv University with a degree in Electronics Engineering.
- Richard Ressler
-
2014年3月以来，Richard Ressler担任公司的信托经理。他是Orchard Capital公司的创始人兼总裁，一家提供咨询及顾问服务的公司（包括CIM集团） Orchard Capital或其附属公司投资。自1994年以来，他担任Orchard Capital总裁。通过他与Orchard Capital 的关系，他担任不同职务，CIM集团和Orchard第一源资产管理（连同其附属公司）投资顾问，他专注于中间市场债券投资。OFSAM及其全资子公司，OFS资本管理有限责任公司，都在证券交易委员会注册为注册投资顾问公司。他担任Orchard Capital或者其附属子公司的一些上市与非上市公司的董事会成员，包括自1997年起，他在j2 Global （纳斯达克JCOM）任职，他担任董事会主席，j2 Global董事。从1997年到2000年，他还担任j2 Global首席执行官 （这些职务的担任需要遵守j2 Global 和Orchard Capital的咨询协议）。他熟知CIM从事业务和运营，在商业管理和金融方面有着丰富经验，这是来自于他在CIM集团工作的经历，包括联合创始人。
Richard Ressler,has served as director and chairman of the Company since March 2014. Mr. Ressler is the founder and President of Orchard Capital Corporation ("Orchard Capital"), a firm through which Mr. Ressler oversees companies in which Orchard Capital or its affiliates invest. Through his affiliation with Orchard Capital, Mr. Ressler serves in various senior capacities with, among others, CIM Group, L.P. (together with its controlled affiliates, "CIM"), a community-focused real estate and infrastructure owner, operator, lender and developer, Orchard First Source Asset Management, LLC (together with its controlled affiliates, "OFSAM"), which provides personnel staffing to OFS Capital Management, LLC, a registered investment adviser focusing primarily on investments in middle market and broadly syndicated US loans, debt and equity positions in collateralized loan obligations and other structured credit investments, OFS CLO Management, LLC, a registered investment adviser focusing primarily on investments in broadly syndicated US loans, and OCV Management, LLC ("OCV"), an investor, owner and operator of technology companies. Mr. Ressler also serves as a board member for various public and private companies in which Orchard Capital or its affiliates invest. Mr. Ressler served as non-executive chairman of the board of Ziff Davis, Inc. (NASDAQ: ZD), formerly known as j2Global, Inc., from 1997 until May 2022. In addition, he has also served as the Chief Executive Officer and President and as a director of CIM Real Estate Finance Trust, Inc. ("CMFT"), a non-listed REIT operated by an affiliate of CIM that invests in net lease core real estate assets as well as real estate loans and other credit investments, since February 2018, and has served as Chairman of its board of directors since August 2018. Mr. Ressler has served as the chairman of the investment risk management committee of CMFT since April 2022 and served as a member of the nominating and corporate governance committee from August 2018 to March 2022. Mr. Ressler served as the Chief Executive Officer, President and a director of CIM Income NAV, Inc. ("CIM Income NAV") from February 2018 to December 2021 and as Chairman of the board of directors of CIM Income NAV from August 2018 to December 2021 until CIM Income NAV's merger with and into CMFT in December 2021. Mr. Ressler served as the Chief Executive Officer and President and as a director of Cole Office & Industrial REIT (CCIT III), Inc. ("CCIT III") from February 2018 and as chairman of its board of directors from August 2018 until CCIT III's merger with and into CMFT in December 2020. Mr. Ressler also served as a director of Cole Office & Industrial REIT (CCIT II), Inc. ("CCIT II") from January 2019 until CCIT II's merger with Griffin Realty Trust, Inc. ("GRT") in March 2021 and as a director of Cole Credit Property Trust V, Inc. ("CCPT V") from January 2019 to October 2019.Mr. Ressler co-founded CIM Group, L.P. in 1994 and serves as the Executive Chairman of CIM and as an officer of various affiliates of CIM, including Creative Media & Community Trust Corporation manager. He chairs CIM's Executive, Investment, Allocation and Real Asset Management Committees. Mr. Ressler co-founded the predecessor of OFSAM in 2001 and chairs its executive committee. Mr. Ressler co-founded OCV in 2016 and chairs its executive committee. Prior to founding Orchard Capital, from 1988 until 1994, Mr. Ressler served as Vice Chairman of Brooke Group Limited, the predecessor of Vector Group, Ltd. (NYSE: VGR) and served in various executive capacities at VGR and its subsidiaries. Prior to VGR, Mr. Ressler was with Drexel Burnham Lambert, Inc., where he focused on merger and acquisition transactions and the financing needs of middle-market companies. Mr. Ressler began his career in 1983 with Cravath, Swaine and Moore LLP, working on public offerings, private placements, and merger and acquisition transactions. Mr. Ressler holds a B.A. from Brown University, and J.D. and M.B.A. degrees from Columbia University. - 2014年3月以来，Richard Ressler担任公司的信托经理。他是Orchard Capital公司的创始人兼总裁，一家提供咨询及顾问服务的公司（包括CIM集团） Orchard Capital或其附属公司投资。自1994年以来，他担任Orchard Capital总裁。通过他与Orchard Capital 的关系，他担任不同职务，CIM集团和Orchard第一源资产管理（连同其附属公司）投资顾问，他专注于中间市场债券投资。OFSAM及其全资子公司，OFS资本管理有限责任公司，都在证券交易委员会注册为注册投资顾问公司。他担任Orchard Capital或者其附属子公司的一些上市与非上市公司的董事会成员，包括自1997年起，他在j2 Global （纳斯达克JCOM）任职，他担任董事会主席，j2 Global董事。从1997年到2000年，他还担任j2 Global首席执行官 （这些职务的担任需要遵守j2 Global 和Orchard Capital的咨询协议）。他熟知CIM从事业务和运营，在商业管理和金融方面有着丰富经验，这是来自于他在CIM集团工作的经历，包括联合创始人。
- Richard Ressler,has served as director and chairman of the Company since March 2014. Mr. Ressler is the founder and President of Orchard Capital Corporation ("Orchard Capital"), a firm through which Mr. Ressler oversees companies in which Orchard Capital or its affiliates invest. Through his affiliation with Orchard Capital, Mr. Ressler serves in various senior capacities with, among others, CIM Group, L.P. (together with its controlled affiliates, "CIM"), a community-focused real estate and infrastructure owner, operator, lender and developer, Orchard First Source Asset Management, LLC (together with its controlled affiliates, "OFSAM"), which provides personnel staffing to OFS Capital Management, LLC, a registered investment adviser focusing primarily on investments in middle market and broadly syndicated US loans, debt and equity positions in collateralized loan obligations and other structured credit investments, OFS CLO Management, LLC, a registered investment adviser focusing primarily on investments in broadly syndicated US loans, and OCV Management, LLC ("OCV"), an investor, owner and operator of technology companies. Mr. Ressler also serves as a board member for various public and private companies in which Orchard Capital or its affiliates invest. Mr. Ressler served as non-executive chairman of the board of Ziff Davis, Inc. (NASDAQ: ZD), formerly known as j2Global, Inc., from 1997 until May 2022. In addition, he has also served as the Chief Executive Officer and President and as a director of CIM Real Estate Finance Trust, Inc. ("CMFT"), a non-listed REIT operated by an affiliate of CIM that invests in net lease core real estate assets as well as real estate loans and other credit investments, since February 2018, and has served as Chairman of its board of directors since August 2018. Mr. Ressler has served as the chairman of the investment risk management committee of CMFT since April 2022 and served as a member of the nominating and corporate governance committee from August 2018 to March 2022. Mr. Ressler served as the Chief Executive Officer, President and a director of CIM Income NAV, Inc. ("CIM Income NAV") from February 2018 to December 2021 and as Chairman of the board of directors of CIM Income NAV from August 2018 to December 2021 until CIM Income NAV's merger with and into CMFT in December 2021. Mr. Ressler served as the Chief Executive Officer and President and as a director of Cole Office & Industrial REIT (CCIT III), Inc. ("CCIT III") from February 2018 and as chairman of its board of directors from August 2018 until CCIT III's merger with and into CMFT in December 2020. Mr. Ressler also served as a director of Cole Office & Industrial REIT (CCIT II), Inc. ("CCIT II") from January 2019 until CCIT II's merger with Griffin Realty Trust, Inc. ("GRT") in March 2021 and as a director of Cole Credit Property Trust V, Inc. ("CCPT V") from January 2019 to October 2019.Mr. Ressler co-founded CIM Group, L.P. in 1994 and serves as the Executive Chairman of CIM and as an officer of various affiliates of CIM, including Creative Media & Community Trust Corporation manager. He chairs CIM's Executive, Investment, Allocation and Real Asset Management Committees. Mr. Ressler co-founded the predecessor of OFSAM in 2001 and chairs its executive committee. Mr. Ressler co-founded OCV in 2016 and chairs its executive committee. Prior to founding Orchard Capital, from 1988 until 1994, Mr. Ressler served as Vice Chairman of Brooke Group Limited, the predecessor of Vector Group, Ltd. (NYSE: VGR) and served in various executive capacities at VGR and its subsidiaries. Prior to VGR, Mr. Ressler was with Drexel Burnham Lambert, Inc., where he focused on merger and acquisition transactions and the financing needs of middle-market companies. Mr. Ressler began his career in 1983 with Cravath, Swaine and Moore LLP, working on public offerings, private placements, and merger and acquisition transactions. Mr. Ressler holds a B.A. from Brown University, and J.D. and M.B.A. degrees from Columbia University.
高管简历
中英对照 | 中文 | 英文- Mark Yung
Mark Yung于2017年12月11日当选为Presbia Plc董事会执行主席兼首席执行官。容先生是OCV Management，LLC“；OCV”；的联合创始人兼管理负责人，OCV”；是一家位于洛杉矶的技术和生命科学公司的投资者，所有者和运营商，该公司成立于2016年，由Richard Ressler（我们的董事之一，也是我们公司大多数普通股的实益拥有人）持有多数股权。此前，他曾担任Orchard Capital公司（他于2006年加入的公司）的董事总经理。通过与OCV和Orchard Capital的合作，容先生一直并将继续担任各种高级职务，其中包括眼科设备公司Presbia Plc（纳斯达克市场代码:LENS）的董事长兼首席执行官，以及Environmental Solutions Worldwide，Inc.的董事会执行主席，一家专注于减少柴油排放的清洁技术公司，担任Polymer Plainfield Holdings，Inc.的首席财务官和董事，该公司是一家OEM汽车供应商，业务遍及美国、加拿大、墨西哥和加勒比地区，担任Vantage Surgical Systems，Inc.的董事会主席，以及担任Coreolis Holdings和Tradewinds Holdings的董事和/或官员。加入Orchard Capital Corp.之前，Yung先生是纽约花旗集团（Citigroup）和荷兰阿姆斯特丹荷兰银行（ABN AMRO）企业战略与并购集团的高级副总裁。担任公司战略职务之前，Yung先生是JPMorgan Partners（“；JPMP”；）的投资专业人士。在JPMP，Yung先生专注于拉丁美洲的风险投资，增长股权和买断交易，并担任该地区各种新兴公司的董事会成员。Yung先生于1996年在Chase Securities，Inc.开始他的职业生涯，专注于跨境收购和私有化的杠杆融资。容先生是Pacwest Bancorp公司（Nasdaq“；PACW”；）的独立董事。Yung先生拥有康奈尔大学（Cornell University）学士学位和欧洲工商管理学院（INSEAD）工商管理硕士学位。
Mark Yung was elected as Executive Chairman of the board and Chief Executive Officer of Presbia PLC on December 11 2017. Mr. Yung is co-founder and Managing Principal of OCV Management, LLC “OCV”, an investor, owner and operator of technology and life science companies based in Los Angeles, which was founded in 2016 and is majority-owned by Richard Ressler (one of our directors and the beneficial owner of the majority of the ordinary shares of our company). Previously, Mr. Yung was a Managing Director at Orchard Capital Corp., a firm he joined in 2006. Through his affiliation with OCV and Orchard Capital, Mr. Yung has and continues to serve in various senior capacities including, among others, as Chairman and CEO of Presbia PLC (NASDAQ: LENS), an ophthalmic device company, as Executive Chairman of the board of directors of Environmental Solutions Worldwide, Inc., a clean technology company focused on the reduction of diesel emissions, as Chief Financial Officer and director of Polymer Plainfield Holdings, Inc., an OEM automotive supplier with operations in the United States, Canada, Mexico and the Caribbean, as Chairman of the Board of Vantage Surgical Systems, Inc., and as director and/or officer of Coreolis Holdings and Tradewinds Holdings. Prior to joining Orchard Capital Corp., Mr. Yung was a Senior Vice President in the Corporate Strategy and Merger and Acquisitions groups of Citigroup in New York and ABN AMRO in Amsterdam, Netherlands. Prior to his corporate strategy roles, Mr. Yung was an investment professional at JPMorgan Partners (“JPMP”). At JPMP, Mr. Yung focused on venture capital, growth equity and buyout transactions in Latin America and served as board member for various emerging companies in the region. Mr. Yung began his career in 1996 at Chase Securities, Inc., focusing on leveraged finance for cross-border buyouts and privatizations. Mr. Yung is an Independent Director of PacWest Bancorp, Inc. (NASDAQ “PACW”). Mr. Yung holds a B.A. from Cornell University and an MBA from INSEAD.- Mark Yung于2017年12月11日当选为Presbia Plc董事会执行主席兼首席执行官。容先生是OCV Management，LLC“；OCV”；的联合创始人兼管理负责人，OCV”；是一家位于洛杉矶的技术和生命科学公司的投资者，所有者和运营商，该公司成立于2016年，由Richard Ressler（我们的董事之一，也是我们公司大多数普通股的实益拥有人）持有多数股权。此前，他曾担任Orchard Capital公司（他于2006年加入的公司）的董事总经理。通过与OCV和Orchard Capital的合作，容先生一直并将继续担任各种高级职务，其中包括眼科设备公司Presbia Plc（纳斯达克市场代码:LENS）的董事长兼首席执行官，以及Environmental Solutions Worldwide，Inc.的董事会执行主席，一家专注于减少柴油排放的清洁技术公司，担任Polymer Plainfield Holdings，Inc.的首席财务官和董事，该公司是一家OEM汽车供应商，业务遍及美国、加拿大、墨西哥和加勒比地区，担任Vantage Surgical Systems，Inc.的董事会主席，以及担任Coreolis Holdings和Tradewinds Holdings的董事和/或官员。加入Orchard Capital Corp.之前，Yung先生是纽约花旗集团（Citigroup）和荷兰阿姆斯特丹荷兰银行（ABN AMRO）企业战略与并购集团的高级副总裁。担任公司战略职务之前，Yung先生是JPMorgan Partners（“；JPMP”；）的投资专业人士。在JPMP，Yung先生专注于拉丁美洲的风险投资，增长股权和买断交易，并担任该地区各种新兴公司的董事会成员。Yung先生于1996年在Chase Securities，Inc.开始他的职业生涯，专注于跨境收购和私有化的杠杆融资。容先生是Pacwest Bancorp公司（Nasdaq“；PACW”；）的独立董事。Yung先生拥有康奈尔大学（Cornell University）学士学位和欧洲工商管理学院（INSEAD）工商管理硕士学位。
- Mark Yung was elected as Executive Chairman of the board and Chief Executive Officer of Presbia PLC on December 11 2017. Mr. Yung is co-founder and Managing Principal of OCV Management, LLC “OCV”, an investor, owner and operator of technology and life science companies based in Los Angeles, which was founded in 2016 and is majority-owned by Richard Ressler (one of our directors and the beneficial owner of the majority of the ordinary shares of our company). Previously, Mr. Yung was a Managing Director at Orchard Capital Corp., a firm he joined in 2006. Through his affiliation with OCV and Orchard Capital, Mr. Yung has and continues to serve in various senior capacities including, among others, as Chairman and CEO of Presbia PLC (NASDAQ: LENS), an ophthalmic device company, as Executive Chairman of the board of directors of Environmental Solutions Worldwide, Inc., a clean technology company focused on the reduction of diesel emissions, as Chief Financial Officer and director of Polymer Plainfield Holdings, Inc., an OEM automotive supplier with operations in the United States, Canada, Mexico and the Caribbean, as Chairman of the Board of Vantage Surgical Systems, Inc., and as director and/or officer of Coreolis Holdings and Tradewinds Holdings. Prior to joining Orchard Capital Corp., Mr. Yung was a Senior Vice President in the Corporate Strategy and Merger and Acquisitions groups of Citigroup in New York and ABN AMRO in Amsterdam, Netherlands. Prior to his corporate strategy roles, Mr. Yung was an investment professional at JPMorgan Partners (“JPMP”). At JPMP, Mr. Yung focused on venture capital, growth equity and buyout transactions in Latin America and served as board member for various emerging companies in the region. Mr. Yung began his career in 1996 at Chase Securities, Inc., focusing on leveraged finance for cross-border buyouts and privatizations. Mr. Yung is an Independent Director of PacWest Bancorp, Inc. (NASDAQ “PACW”). Mr. Yung holds a B.A. from Cornell University and an MBA from INSEAD.
- Casey Lind
Casey Lind自2018年2月起担任首席运营官。在加入Presbia之前，Lind女士于2017年10月至2018年2月担任私人咨询公司Pathfinder Global Way，LLC的管理成员。在此之前，从1998年到2017年6月，她曾任职Alcon公司（诺华纽约证券交易所代码:NVS），在那里她曾担任越来越重要的职务，包括领导早期手术青光眼和药物输送研发团队，最近担任Retina Group的项目负责人。Lind女士拥有众多已发布的专利，专注于药物输送，注射控制，基于MEMS的后段引流和流动以及相变药物制剂的制造工艺。Lind女士在眼科世界领袖（OWL）在国家和地方两级都发挥了积极作用。她是猫头鹰冠军成员，并通过积极规划和主持南加州猫头鹰分会会议，在执行会员委员会和当地的国家层面做出贡献。Lind女士毕业于爱荷华州立大学（Iowa State University），获得商学学位，并在韦伯斯特大学（Webster University）获得工商管理硕士学位。
Casey Lind has served as Chief Operating Officer since February 2018. Prior to joining Presbia, from October 2017 to February 2018 Ms. Lind was the managing member of Pathfinder Global Way, LLC, a private consulting company. Prior to that, from 1998 to June 2017 Ms. Lind worked for Alcon, a Novartis NYSE: NVS company, where she held positions of increasing responsibilities, including leading the early Surgical Glaucoma and Drug Delivery R&D teams and most recently as a Project Head for the Retina group. Ms. Lind has numerous issued patents focused on drug delivery, injection control, MEMS based posterior segment drainage and flow, and manufacturing processes for phase transition drug formulations. Ms. Lind has an active role at both the national and local level in Ophthalmic World Leaders (OWL). She is an OWL Champion Member and contributes at the national level on the Executive Membership Committee, and locally, by actively planning and moderating Southern California OWL chapter meetings. Ms. Lind is a graduate of Iowa State University, with a degree in Business, and received her MBA from Webster University.- Casey Lind自2018年2月起担任首席运营官。在加入Presbia之前，Lind女士于2017年10月至2018年2月担任私人咨询公司Pathfinder Global Way，LLC的管理成员。在此之前，从1998年到2017年6月，她曾任职Alcon公司（诺华纽约证券交易所代码:NVS），在那里她曾担任越来越重要的职务，包括领导早期手术青光眼和药物输送研发团队，最近担任Retina Group的项目负责人。Lind女士拥有众多已发布的专利，专注于药物输送，注射控制，基于MEMS的后段引流和流动以及相变药物制剂的制造工艺。Lind女士在眼科世界领袖（OWL）在国家和地方两级都发挥了积极作用。她是猫头鹰冠军成员，并通过积极规划和主持南加州猫头鹰分会会议，在执行会员委员会和当地的国家层面做出贡献。Lind女士毕业于爱荷华州立大学（Iowa State University），获得商学学位，并在韦伯斯特大学（Webster University）获得工商管理硕士学位。
- Casey Lind has served as Chief Operating Officer since February 2018. Prior to joining Presbia, from October 2017 to February 2018 Ms. Lind was the managing member of Pathfinder Global Way, LLC, a private consulting company. Prior to that, from 1998 to June 2017 Ms. Lind worked for Alcon, a Novartis NYSE: NVS company, where she held positions of increasing responsibilities, including leading the early Surgical Glaucoma and Drug Delivery R&D teams and most recently as a Project Head for the Retina group. Ms. Lind has numerous issued patents focused on drug delivery, injection control, MEMS based posterior segment drainage and flow, and manufacturing processes for phase transition drug formulations. Ms. Lind has an active role at both the national and local level in Ophthalmic World Leaders (OWL). She is an OWL Champion Member and contributes at the national level on the Executive Membership Committee, and locally, by actively planning and moderating Southern California OWL chapter meetings. Ms. Lind is a graduate of Iowa State University, with a degree in Business, and received her MBA from Webster University.
- Valeriano Lima
Valeriano Lima自2019年2月起担任Presbia Plc公司财务总监。他曾于2018年2月至2018年2月担任Presbia Plc财务和战略高级经理，并于2015年11月至2018年2月担任Presbia Plc财务经理。Lima先生于2015年担任Google，Inc.的高级财务分析师，并于2008年至2012年担任BT Group，plc（“英国电信”）的高级财务分析师。Lima先生拥有加州州立大学圣贝纳迪诺分校（California State University，San Bernardino）的B.S.学位和圣母大学（University of Notre Dame）的工商管理硕士学位。
Valeriano Lima has served as Corporate Controller of Presbia PLC since Feburary 2019. He previously served as Senior Manager, Finance and Strategy of Presbia PLC from February 2018 to February 2018, and as Finance Manager of Presbia PLC from November 2015 to February 2018. Mr. Lima served as Senior Financial Analyst at Google, Inc. in 2015 and Senior Financial Analyst at BT Group, PLC ("British Telecom") from 2008 to 2012. Mr. Lima holds a B.S. degree from California State University, San Bernardino and an MBA from the University of Notre Dame.- Valeriano Lima自2019年2月起担任Presbia Plc公司财务总监。他曾于2018年2月至2018年2月担任Presbia Plc财务和战略高级经理，并于2015年11月至2018年2月担任Presbia Plc财务经理。Lima先生于2015年担任Google，Inc.的高级财务分析师，并于2008年至2012年担任BT Group，plc（“英国电信”）的高级财务分析师。Lima先生拥有加州州立大学圣贝纳迪诺分校（California State University，San Bernardino）的B.S.学位和圣母大学（University of Notre Dame）的工商管理硕士学位。
- Valeriano Lima has served as Corporate Controller of Presbia PLC since Feburary 2019. He previously served as Senior Manager, Finance and Strategy of Presbia PLC from February 2018 to February 2018, and as Finance Manager of Presbia PLC from November 2015 to February 2018. Mr. Lima served as Senior Financial Analyst at Google, Inc. in 2015 and Senior Financial Analyst at BT Group, PLC ("British Telecom") from 2008 to 2012. Mr. Lima holds a B.S. degree from California State University, San Bernardino and an MBA from the University of Notre Dame.